| Cytokine release syndrome |
246 |
| Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations |
176 |
| Targeting adenosine for cancer immunotherapy |
81 |
| Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors |
68 |
| A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors |
63 |
| The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors |
62 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable |
58 |
| Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
56 |
| The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) |
55 |
| Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after >= 1 year of follow-up: JAVELIN Merkel a phase 2 clinical trial |
53 |
| Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab |
53 |
| Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy |
50 |
| Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study |
50 |
| Targeting the TGF beta pathway with galunisertib, a TGF beta RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade |
50 |
| Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) |
47 |
| Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature |
46 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations |
44 |
| Exploring the emerging role of the microbiome in cancer immunotherapy |
43 |
| Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma |
40 |
| Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience |
40 |
| Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study |
40 |
| The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) |
39 |
| Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma |
38 |
| Oncolytic virus immunotherapy: future prospects for oncology |
38 |
| Tumor mutational burden quantification from targeted gene panels: major advancements and challenges |
36 |
| Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma |
33 |
| Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study |
33 |
| Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option |
33 |
| Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance |
33 |
| Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma |
32 |
| Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis |
32 |
| Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment |
32 |
| Soluble immune checkpoints in cancer: production, function and biological significance |
32 |
| Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics |
31 |
| Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis |
31 |
| Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease |
31 |
| CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma |
31 |
| Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients |
31 |
| Mechanisms regulating PD-L1 expression on tumor and immune cells |
30 |
| Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab |
30 |
| Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson |
29 |
| STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. |
29 |
| Monalizumab: inhibiting the novel immune checkpoint NKG2A |
29 |
| Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide |
28 |
| Collagen density regulates the activity of tumor-infiltrating T cells |
28 |
| Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study |
28 |
| Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis |
27 |
| Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity |
27 |
| Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches |
26 |
| Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events |
26 |
